Stocksigma LogoStocksigma Logo

USFDA Concludes Inspection at Rubicon Research's Ambernath Facility with Five Observations

The USFDA conducted an unannounced comprehensive GMP and product-filing inspection at Rubicon Research's Ambernath manufacturing facility from 21st Oct'26

USFDA Concludes Inspection at Rubicon Research's Ambernath Facility with Five Observations

Rubicon Research Ltd 路 Others (Uncategorized) 路 30 Oct 2026, 5:53 am

USFDA Concludes Inspection at Rubicon Research's Ambernath Facility with Five Observations The USFDA conducted an unannounced comprehensive GMP and product-filing inspection at Rubicon Research's Ambernath manufacturing facility from 21st Oct'26 to 29th Oct'26. The regulator issued a Form 483 with five observations: three concerning system improvements and two regarding the product application under review. All observations are procedural with no data integrity issues. Across other sites, R&D units in Canada and Thane hold EIRs with zero observations, New Jersey holds VAI status, while responses have been submitted for Pithampur and Satara inspections.

Original exchange filing (PDF)

More announcements from Rubicon Research Ltd

All Rubicon Research Ltd announcements